15 results about "Plasmin activity" patented technology

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention belongs to the technical field of food, and particularly relates to application of nisin in inhibiting plasmin activity and improving quality of milk and / or dairy products. The nisin disclosed by the invention can be used for remarkably inhibiting the activity of plasmin. The nisin disclosed by the invention is a food additive allowed to be used, the INS number is 234, and the nisin is high in safety. Plasmin is a key enzyme causing deterioration of milk and milk quality, and the nisin disclosed by the invention improves the quality of milk and / or dairy products from the source by inhibiting the activity of plasmin.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

To provide an antigen-binding protein comprising an antigen-binding domain that binds to plasmin. Also provided are compositions comprising the antigen binding proteins, as well as uses thereof and methods of treatment comprising the same.SOLUTION: To provide antigen-binding proteins or antigen-binding fragments thereof that specifically bind to the serine protease domain of plasmin and inhibit or reduce plasmin activity via interaction with the catalytic site of the protein.SELECTED DRAWING: None

The present disclosure provides an ADC comprising a plasmin cleavage site. The ADC according to the present disclosure can have a hydrophobic portion between an antibody and a plasmin cleavage site, and the hydrophobic portion includes no uncharged hydrophilic polymers such as polyethylene glycol (PEG).

The invention discloses a fermented soybean fermentation process for high-yield plasmin and thrombolysis application thereof. According to the method, black beans are used as raw materials, water is added for soaking and sterilization, bacillus subtilis is added, the mixture is put into a constant-temperature and constant-humidity incubator for fermentation, according to plasmin activity, the fermentation temperature, humidity, time, inoculation amount, loading capacity and solid-liquid ratio are subjected to a single-factor test, the solid-state fermentation conditions are optimized, and the plasmin solid-state fermentation effect is improved. An optimal solid-state fermentation process is determined by combining an orthogonal test, high-plasmin-yield fermented soybean is obtained through an ultralow-temperature freeze-drying technology, and finally, the safety and thrombolysis effect of the plasmin of the fermented soybean are verified through in-vivo and in-vitro thrombolysis experiments. Compared with the traditional processing process, the fermented soybean processed by the method disclosed by the invention has the advantages that the influence of seasonal and environmental conditions is reduced by utilizing the principle of pure fermentation, the quality stability of the fermented soybean is improved, and meanwhile, the production of the fermented soybean with high plasmin yield lays a foundation for the development of thrombolytic drugs.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The invention belongs to the technical field of dairy product processing, and discloses a buffalo formula milk quality monitoring method. According to the method, the raw material key indexes and the whole-flow process data of the buffalo formula milk are obtained in real time through the online sensor network, second-level calculation is carried out by utilizing the special dynamic model, and the plasmin activity of the buffalo formula milk can be predicted in real time before product packaging is completed. According to the method, quality control is converted from finished product sampling inspection depending on lag to process prediction based on real-time data for the first time, and real preventive quality control is achieved. According to the method, through source risk instant grading and production process real-time deviation correction, disqualification of the whole batch of products caused by high-risk raw materials or process deviation can be effectively prevented, and the quality loss is greatly reduced. And meanwhile, the dependence on frequent and destructive off-line sampling inspection is reduced, and the detection cost and time are saved.

This invention relates to compositions and methods for detecting hyperfibrinolysis in a blood sample using a reagent including surfactant, an exogenous plasmin substrate, and optionally poly-lysine. Methods for detecting a fibrinolytic abnormality in a subject, monitoring the effectiveness of a treatment for hyperfibrinolysis, and guiding treatment of a patient in need of treatment for bleeding are also provided.

A compound of formula (I) capable of inhibiting plasmin activity, delaying fibrinolysis, and having coagulation and hemostatic activity, pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof, wherein X, and R1 to R5 are as defined in the description.

The present invention relates to a method of preparing a casein hydrolysate by hydrolysis of casein with endogenous plasmin, and the casein hydrolysate obtainable by the method. In particular, the present invention relates to a method of preparing a casein hydrolysate without adding any exogenous enzymes such that an organic casein hydrolysate is obtained.